InterVenn Biosciences Philippines solidified its hold in the Southeast Asian region with the grand launch of its state-of-the-art office in the heart of Ortigas Center, Pasig City last Friday, July 22, 2022.
While the company is headquartered in the Bay Area of San Francisco, California, the team that maintains the AI technology is made up mostly of Filipinos residing in the Philippines, from which its co-founder and CEO, Aldo Carrascoso, also hails.
“InterVenn has made significant progress in early cancer detection thanks to the brilliant and dedicated Filipino engineers we have on board. They help build and maintain the front end, back end, and cloud infrastructure of our next-generation liquid biopsy, as we all work together to reach a world where no one should ever be blindsided by disease,” Carrascoso said, when discussing how its products GLORI™ and DAWN™ came to be.
The new site located at the Podium West Tower will expand the local team’s roster of developers and engineers that form the backbone running the proprietary AI technology used in the company’s research. Currently, over 100 Filipinos work on the software engineering stream of InterVenn, with plans to recruit more local talent as they further expand their business in the region.
“One hundred percent of our software is proudly Philippine-made. We started this venture with the goal of not just having the means of finding a cure and early detection for cancer, but to also showcase to everyone that we Filipinos can achieve this on a global scale,” said InterVenn Philippines General Manager Axel Kornerup, who also proudly shared that InterVenn has been collaborating with local oncologists in running the VOCAL (InterVenn Ovarian Cancer Liquid Biopsy) testing program.
The company, armed with its new facilities and cadre of researchers, has been aggressive in its recruitment and expansion to support the development and commercialization of DAWN™, which they unveiled last month in the health industry’s largest conference for oncology ASCO 2022. Its application on other tumor types is continuously being studied.
“Our research is a major step towards truly universal healthcare. We’re proud to be making these phenomenal developments in the Philippines, and we look forward to working with more local stakeholders in the future,” said Carrascoso.